Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients

scientific article published on 01 October 1991

Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JAC/28.SUPPL_B.93
P953full work available at URLhttp://academic.oup.com/jac/article-pdf/28/suppl_B/93/2023885/28-suppl_B-93.pdf
P698PubMed publication ID1778896

P50authorAnthony H. GoldstoneQ110167848
P2093author name stringS. Blair
J. Strang
R. Chopra
K. G. Patterson
P. Cervi
P407language of work or nameEnglishQ1860
P921main subjectpharmacologyQ128406
amphotericin BQ412223
P1104number of pages12
P304page(s)93-104
P577publication date1991-10-01
P1433published inJournal of Antimicrobial ChemotherapyQ6294770
P1476titleLiposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients
P478volume28 Suppl B

Reverse relations

cites work (P2860)
Q40471190Amphotericin B Toxicity Reduced by Administration in Fat Emulsion
Q41378026Diversity of lipid-based polyene formulations and their behavior in biological systems
Q44874051Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes
Q36757947Effects of the aggregation state of amphotericin B on its toxicity to mice
Q33606840Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review
Q40965923Engineering liposomes for drug delivery: progress and problems
Q42544559In search of the amazing technicolour dream coat for amphotericin B.
Q72136291In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex
Q35041474Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis
Q43506628Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study
Q35372178Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics
Q40899101Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections
Q40485546Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential
Q40774494Management of immunocompromised patients with evidence of an invasive mycosis.
Q33752450Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
Q35136556Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
Q41108756Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
Q44861655The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection
Q42573016Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema
Q73013285[Amphotericin B deoxycholate (Fungizone): old drug, new versions]
Q73200587[Amphotericin B deoxycholate (Fungizone): old drug, new versions]

Search more.